Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 35.6 USD 0.03% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Research & Development
-$103.5m
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-18%
Johnson & Johnson
NYSE:JNJ
Research & Development
-$16.4B
CAGR 3-Years
-5%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.5B
CAGR 3-Years
1%
CAGR 5-Years
-13%
CAGR 10-Years
-10%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Research & Development
-$16B
CAGR 3-Years
-17%
CAGR 5-Years
-13%
CAGR 10-Years
-9%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$10.5B
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-8%
No Stocks Found

Supernus Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Pharmaceuticals

Supernus Pharmaceuticals Inc. weaves a distinctive narrative within the realm of specialty pharmaceuticals, primarily zeroing in on the development and commercialization of products that address unmet medical needs in central nervous system (CNS) diseases. Founded in 2005 and headquartered in Rockville, Maryland, the company has become a nimble player in the pharmaceutical landscape, leveraging its expertise in product development to create a portfolio that caters to a range of CNS conditions, including epilepsy, migraine, attention-deficit/hyperactivity disorder (ADHD), and bipolar disorder. By focusing on these complex and often challenging areas, Supernus not only pushes the envelope of pharmaceutical innovation but also aligns its mission closely with improving quality of life for patients enduring these conditions. Financially, Supernus drives its revenue through both its proprietary portfolio and strategic partnerships that expand its market reach. Central to its business model is the commercialization of FDA-approved medications such as Trokendi XR and Qelbree, which cater to specific patient needs within the CNS domain. The company's growth is augmented by an adept blend of internal research & development and acquisitions, enabling it to enhance its pipeline and expand its therapeutic offerings. Partnerships and collaborations with other pharmaceutical entities elevate its market penetration, while a solid sales and distribution network ensures its products efficiently reach healthcare providers and patients. This strategic approach allows Supernus to maintain a robust revenue stream while steadily investing in future drug development programs, fostering long-term growth and sustainability within the competitive pharmaceutical sector.

SUPN Intrinsic Value
43.97 USD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Supernus Pharmaceuticals Inc's Research & Development?
Research & Development
-103.5m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Research & Development amounts to -103.5m USD.

What is Supernus Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-18%

Over the last year, the Research & Development growth was -20%. The average annual Research & Development growth rates for Supernus Pharmaceuticals Inc have been -6% over the past three years , -6% over the past five years , and -18% over the past ten years .

Back to Top